Ratings Sartorius Stedim Biotech

Equities

DIM

FR0013154002

Market Closed - Euronext Paris Other stock markets 11:39:03 2024-04-30 am EDT			5-day change	1st Jan Change
203 ^EUR	-3.20%		+3.31%	-15.24%

Apr. 23	SARTORIUS STEDIM BIOTECH : Barclays reaffirms its Neutral rating	ZD
Apr. 22	Sartorius Stedim: in the red with brokerage comments	CF

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
The company returns high margins, thereby supporting business profitability.
Over the past four months, analysts' average price target has been revised upwards significantly.

Weaknesses

The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
With an expected P/E ratio at 58.13 and 41.94 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
The company's "enterprise value to sales" ratio is among the highest in the world.
The company appears highly valued given the size of its balance sheet.
The company is highly valued given the cash flows generated by its activity.
The company is not the most generous with respect to shareholders' compensation.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
Revenue estimates are regularly revised downwards for the current and coming years.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
Over the past twelve months, analysts' opinions have been revised negatively.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.	ESG Refinitiv
SARTORIUS STEDIM BIOTECH	-15.24%	21.86B	B
ABBOTT LABORATORIES	-3.72%	186B	C+
MEDTRONIC PLC	-2.60%	107B	C
BECTON, DICKINSON AND COMPANY	-3.79%	67.44B	A
DEXCOM, INC.	+2.66%	50.03B	B-
CENCORA, INC.	+16.39%	47.81B	B-
HOYA CORPORATION	+4.79%	41.03B	B+
METTLER-TOLEDO INTERNATIONAL, INC.	+1.38%	26.85B	B
WEST PHARMACEUTICAL SERVICES, INC.	+1.52%	25.82B	A-
ZIMMER BIOMET HOLDINGS, INC.	-1.17%	25.01B	B

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes